Slide 1: Coffee Microcaps
1 1 COFFEE MICROCAPS 30 NOVEMBER , 2023 NASDAQ: IMRN ASX: IMC Steven Lydeamore - CEO
Slide 2: Safe Harbor Statement
2 2 Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended
Slide 3: Revenue Generating with Strong Pipeline
3 3 REVENUE GENERATING WITH STRONG PIPELINE Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Financial Snapshot 227,798,346 Shares on Issue 15,568,559
Slide 4: Revenue Generating with Strong Pipeline: Status Update
4 4 REVENUE GENERATING WITH STRONG PIPELINE Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Status at Coffee Microcaps - 30 November 2023 Status at Co
Slide 5: Technology Platform for Gut Mediated Diseases
5 5 TECHNOLOGY PLATFORM FOR GUT MEDIATED DISEASES Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxida se, growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared
Slide 6: Strong Sales Growth in Attractive Market
6 6 STRONG SALES GROWTH IN ATTRACTIVE MARKET Industry tailwinds Travel picking up significantly following COVID lockdowns $83m Based on US annual travel numbers and a penetration rate of 15%, the market potential is estimated at $83m 5 $50m Based on EU travel numbers and a penetration rate of 15%, t
Slide 7: Distribution Capability
7 7 DISTRIBUTION CAPABILITY Australia • Retail network includes over 3,500 pharmacies • Online sales of both Travelan® and Protectyn® • Protectyn® is distributed by Osborne Health Supplies USA • Travelan® is sold to travel medicine clinics and on our own amazon.com shopfront (launched July 2023) • R
Slide 8: Strong Pipeline with Near Term Milestones
8 8 STRONG PIPELINE WITH NEAR TERM MILESTONES 8 8 Market Phase III Phase II Phase I Partner Compound or brand name Travelan® CampETEC Market Phase III Phase II Phase I Indication Compound or brand name Traveler’s Diarrhea ETEC challenge IMM - 124E Travelan® Clostridioides difficile Infection & Recur
Slide 9: Valuable Sales Potential for Pipeline Products
9 9 VALUABLE SALES POTENTIAL FOR PIPELINE PRODUCTS Corporate › Immuron’s development of IMM - 124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need › Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonstrating
Slide 10: Near Term Milestones Anticipated to Drive Value
10 10 NEAR TERM MILESTONES ANTICIPATED TO DRIVE VALUE • Topline results for IMM - 124E ETEC 2 clinical trial • Clinical Study Report • 100% of patients enrolled • Completion of In - patient phase ETEC 2 CHIM 3 clinical trial • IRB Approval 4 • Initiated IMM - 124E ETEC 2 CHIM 3 clinical trial • FDA
Slide 11: Scientific References
11 11 SCIENTIFIC REFERENCES Travelan® (IMM - 124E) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Military Health System Research
Slide 12: Contact Information
12 12 EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +613 8892 4854 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: